Entera Bio Ltd. Free Cash Flow

Free Cash Flow of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow growth rates and interactive chart. Free cash flowis calculated as operating cash flow minus of capital expenditures. Interest payments are excluded from the generally accepted definition of free cash flow. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. Some investors prefer FCF or FCF per share over earnings and earnings per share as a measure of profitability. However, because FCF accounts for investments in property, plant, and equipment it can be lumpy over time. Free cash flow is usually used in discounted cash flow models to determine a company's intrinsic value.


Highlights and Quick Summary

  • Free Cash Flow for the quarter ending June 29, 2020 was $-3.53 Million (a 31.32% increase compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow increased by 112.28%
  • Annual Free Cash Flow for 2019 was $-8.96 Million (a -9.17% decrease from previous year)
  • Annual Free Cash Flow for 2018 was $-9.86 Million (a 115.51% increase from previous year)
  • Twelve month Free Cash Flow ending June 29, 2020 was $-11.1 Million (a 14.45% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow increased by 36.62% year-over-year
Trailing Free Cash Flow for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-11.1 Million $-9.68 Million $-8.96 Million $-8.11 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow of Entera Bio Ltd.

Most recent Free Cash Flowof ENTX including historical data for past 10 years.

Interactive Chart of Free Cash Flow of Entera Bio Ltd.

Entera Bio Ltd. Free Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3.53 $-2.69
2019 $-3.2 $-1.66 $-2.13 $-1.97 $-8.96
2018 $-2.35 $-2.24 $-2.76 $-2.51 $-9.86
2017 $-4.58 $-4.58

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.